Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is well-positioned to take advantage of the growing demand for alternative treatments to chronic corticosteroids and immunosuppressants for rare autoimmune diseases, with a focus on developing innovative antibody-based therapies. The company's recent FDA approvals for Vyvgart offer a convenient and effective treatment option, and its pipeline shows significant promise for addressing a range of rare autoimmune diseases. The company's strong management team and solid financials, including a projected multi-billion-dollar opportunity for their IMNM treatment, make argenx a promising investment choice for the future.

Bears say

argenx is experiencing success with FDA approvals for their leading product Vyvgart (efgartigimod) for the treatment of rare autoimmune diseases such as generalized myasthenia gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and now dermatomyositis (DM). However, the market for these diseases is relatively small, and conventional therapies still dominate treatment options for physicians. Therefore, the company may struggle with achieving significant revenue growth and maintaining a competitive edge in a highly saturated market.

argenx (ARGX) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 18 analysts, argenx (ARGX) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,166.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,166.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.